Griffiths Sarah L, Grainger David J
Department of Medicine, University of Cambridge, UK.
Bioessays. 2006 Jun;28(6):629-41. doi: 10.1002/bies.20418.
Metabolic Syndrome is a cluster of risk factors (including obesity, hypertension and insulin resistance), which is associated with late-onset diabetes and coronary heart disease. Elevated levels of the protease inhibitor PAI-1 are well-known molecular markers of the Metabolic Syndrome. Here, however, we present a hypothesis that PAI-1 acts as a causative factor in the development of Metabolic Syndrome and its clinical sequelae. We propose that PAI-1 inhibits the activity of members of the proprotein convertase (PC) class of serine proteases and that this underlies, at a molecular level, many of the other features of the Metabolic Syndrome cluster.
代谢综合征是一组风险因素（包括肥胖、高血压和胰岛素抵抗），与迟发性糖尿病和冠心病相关。蛋白酶抑制剂PAI-1水平升高是代谢综合征众所周知的分子标志物。然而，在此我们提出一个假说，即PAI-1在代谢综合征及其临床后遗症的发生发展中起致病作用。我们认为PAI-1抑制丝氨酸蛋白酶原蛋白转化酶（PC）类成员的活性，并且在分子水平上，这是代谢综合征组群许多其他特征的基础。
